Vyome Holdings, Inc. (NASDAQ:HIND) Receives Consensus Rating of “Hold” from Brokerages

Vyome Holdings, Inc. (NASDAQ:HIND) has been assigned an average recommendation of “Hold” from the five analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $15.00.

Several analysts recently weighed in on HIND shares. Zacks Research raised Vyome to a “hold” rating in a report on Wednesday, May 6th. Litchfield Hills Research assumed coverage on Vyome in a report on Monday, May 4th. They set a “buy” rating on the stock. Finally, Weiss Ratings upgraded Vyome from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, May 1st.

Hedge Funds Weigh In On Vyome

A hedge fund recently bought a new position in Vyome stock. Millennium Management LLC purchased a new stake in Vyome Holdings, Inc. (NASDAQ:HIND) in the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 45,144 shares of the company’s stock, valued at approximately $155,000. Millennium Management LLC owned 0.80% of Vyome as of its most recent filing with the SEC. Institutional investors own 22.06% of the company’s stock.

Vyome Stock Performance

NASDAQ:HIND opened at $2.25 on Friday. Vyome has a one year low of $1.75 and a one year high of $18.60. The business’s 50-day simple moving average is $2.16 and its 200 day simple moving average is $2.58. The stock has a market cap of $15.79 million, a price-to-earnings ratio of -0.18 and a beta of 1.49.

Vyome (NASDAQ:HIND) last released its earnings results on Tuesday, May 12th. The company reported ($0.15) EPS for the quarter. The firm had revenue of $0.03 million during the quarter. On average, equities research analysts predict that Vyome will post -0.6 EPS for the current year.

Vyome Company Profile

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.